StageAcquired | Acquired
About Alios BioPharma
Alios BioPharma is a privately-held biotechnology company located in South San Francisco, CA, that is developing novel medicines aimed at the treatment of viral diseases. Alios has an innovative team of highly experienced scientists and clinical researchers who are developing direct acting antiviral agents against several human viral pathogens of public health importance including respiratory viruses, and other chronic, acute and emerging viral diseases. The overall goal for the Alios therapeutic platform is to maximize patient benefits in areas of high unmet medical need through optimization of potency, safety and tolerability.
Missing: Alios BioPharma's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Alios BioPharma's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Alios BioPharma Patents
Alios BioPharma has filed 70 patents.
The 3 most popular patent topics include:
- Animal virology
- Designer drugs
V8SuperTourer drivers, Animal virology, Inflammations, Trifluoromethyl compounds, Designer drugs
V8SuperTourer drivers, Animal virology, Inflammations, Trifluoromethyl compounds, Designer drugs
Latest Alios BioPharma News
May 12, 2022
News provided by Share this article Share this article BERKELEY, Calif., May 12, 2022 /PRNewswire/ -- Actym Therapeutics, a privately held biotechnology company developing STACT, a novel therapeutic platform that delivers immunomodulatory payloads to solid tumors after IV dosing, announced today the significant expansion of its senior leadership team. Dr. Julie Cherrington joins as BOD Chair, James Stutz joins as Chief Business Officer, and Dr. Omkar Joshi joins as Vice President, Technical Operations. The appointments strengthen the Company's strategic, finance, operations, and technical functions. "On behalf of the Executive Leadership Team and the Board of Directors, we are thrilled to welcome this accomplished group of leaders to Actym." "Each individual brings a proven track record of success in the biotechnology industry. These appointments significantly expand our ability to advance our pipeline, with the ultimate goal of bringing therapeutic benefit to cancer patients with limited treatment options. " Julie Cherrington PhD, Chair, Board of Directors Julie is an accomplished life science executive with extensive insight in bringing drugs into the clinic and through to commercialization. She has been a key contributor to the successful development of multiple FDA-approved products, including SUTENT®, PALLADIA®, VISTIDE®, VIREAD®, and HEPSERA®. Julie has served as President and Chief Executive Officer at several biotechnology companies, including QUE Oncology, Arch Oncology, Revitope Oncology, Zenith Epigenetics, and Pathway Therapeutics. In addition, she served as President and Executive Vice President, R&D at Phenomix Corporation. Earlier in her career, Julie was Vice President of Preclinical and Clinical Research at SUGEN, a Pharmacia/Pfizer company. Julie began her career at Gilead Sciences, where she held a range of positions of increasing responsibility. Currently, Julie serves on the Boards of Syncona Ltd, Sardona Therapeutics, KisoJi Biotechnology, MycRx, Vaxart, and Mirati Therapeutics. Julie received her PhD training in Immunology & Microbiology from the University of Minnesota and Stanford University, and completed a postdoctoral fellowship at UCSF. James Stutz, Chief Business Officer James is an experienced life sciences executive with 20 years in the biopharma industry. He was previously Vice President and Head of Business Development at Instil Bio. Before joining Instil, James was the Chief Financial Officer at Tolerion, and Chief Business Officer at Tioma Therapeutics. James has also held roles of increasing responsibility at InterMune, CoMentis, and Alios BioPharma, which was acquired by Janssen Pharmaceutical Companies of Johnson & Johnson, in November 2014. While at Alios BioPharma, James served as the Vice President of Strategy & Business Development, where he supported the company's CBO and was responsible for business development, financial and strategic planning. In addition to operating roles, James was a Principal with Essex Woodlands Health Ventures where he focused on investments in the biopharma and life sciences tools space including ProteinSimple (acquired by BioTechne), Revance Therapeutics, and Symphogen (acquired by Servier). Prior to his career in life sciences, James was a commissioned officer in the United States Air Force. James graduated with honors, from UC Santa Barbara with a B.A. in Business Economics. He also earned an M.B.A from the Tuck School of Business at Dartmouth. From 2012 through 2017 James held an appointment as Lecturer at Stanford University in the Department of Medicine, Division of Clinical Pharmacology in the School of Medicine. As Chief Business Officer, James will serve as a member of the Actym Executive Leadership Team and be responsible for leading business development, finance, and operations activities for the company. Omkar Joshi PhD, Vice President, Technical Operations Omkar was previously Senior Director, MSAT (Manufacturing Sciences and Technology) at Bayer. In his 16-year career at Bayer, he held roles of increasing responsibility, spanning Drug Substance and Drug Product Process Development, Analytical Development and Preclinical Research. He has extensive experience working across various modalities including recombinant proteins, monoclonal antibodies, ADCs, cell therapies and gene therapies. Omkar earned a PhD in Chemical Engineering from the Oregon State University. As Vice President, Technical Operations, Omkar will serve as a member of the Actym Executive Leadership Team and will be responsible for all aspects of technical development, manufacturing, analytical development, and quality at Actym. About Actym Actym Therapeutics, based in Berkeley, CA, is a privately-held biotechnology company focused on discovery and development of novel immuno-oncology therapies to treat cancer. The company has developed a patent-protected, attenuated, microbial-based, immunotherapeutic technology platform called STACT (S. Typhimurium-Attenuated Cancer Therapy). In preclinical studies, STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. Many of these payload targets are of significant interest to the biopharmaceutical community but are intractable using conventional approaches due to systemic toxicities after intravenous dosing. Furthermore, STACT has been engineered to deliver payload combinations, which facilitates engagement of multiple biological pathways from a single therapy. In April of 2020, Actym raised $34 million in a Series A financing, co-led by Boehringer-Ingelheim Venture Fund and Panacea Venture, with participation from Illumina Ventures, Korea Investment Partners, and JLo Ventures. Media Contact:
Alios BioPharma Frequently Asked Questions (FAQ)
When was Alios BioPharma founded?
Alios BioPharma was founded in 2006.
Where is Alios BioPharma's headquarters?
Alios BioPharma's headquarters is located at 260 East Grand Ave, South San Francisco.
What is Alios BioPharma's latest funding round?
Alios BioPharma's latest funding round is Acquired.
How much did Alios BioPharma raise?
Alios BioPharma raised a total of $73M.
Who are the investors of Alios BioPharma?
Investors of Alios BioPharma include Johnson & Johnson, Roche Venture Fund, SR One, Novartis Venture Funds, Novo Ventures and 3 more.
Who are Alios BioPharma's competitors?
Competitors of Alios BioPharma include Achillion Pharmaceuticals, Idenix Pharmaceuticals, Trimeris, Calibrant Biosystems, Arbor Fuel and 13 more.
Compare Alios BioPharma to Competitors
Avigenics is a company that received a SBIR Phase I grant for a project entitled: Production of Transgenic Poultry Resistant to Avian Influenza Infection by RNAi. Their project generates transgenic poultry resistant to avian influenza (AI) virus through RNA interference (RNAi) technology. Poultry are vulnerable to AI infections that can rapidly reach mortality rates approaching 100%. Current vaccines provide only limited protection, with prophylaxis based on surveillance and diagnosis, followed by rapid depopulation and disposal of infected or exposed birds and quarantine and disinfection of farms and equipment. RNAi technology is a new strategy that could be applied to the inhibition of AI virus replication, representing a paradigm shift in the way to deal with the challenges of AI. Phase I objectives are (i) to generate ALV vectors hosting short interfering RNA (siRNA), (ii) establish stable cell lines hosting siRNAs vectors and (iii) test the efficacy of siRNAs against AI viruses. Three siRNAs shown to effectively inhibit AI viruses will be used to generate cell lines, which will be challenged with 5 different AI viruses to determine whether these vectors, when integrated into the avian genome, can effectively inhibit AI viruses. The broader impact of this research will be to improve the biosecurity of biopharmaceutical production in poultry as the avian influenza virus spreads and well as potentially protecting the food supply from natural as well as bioterrorist threats should these transgenic chickens gain wide approval in the marketplace.
GangaGen is a biotechnology company focused on the development of products for the prevention and treatment of bacterial infections, particularly infections that are resistant to antibiotics, through the application of contemporary molecular and clinical sciences.
Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).
BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.
Pulmotect develops host-directed or pathogen-agnostic products to reduce morbidity and mortality in patients at risk of severe respiratory diseases. It offers immunomodulatory and pathogen-agnostic approaches to prevent and treat respiratory complications. The company was founded in 2007 and is based in Houston, Texas.
Arisyn Therapeutics Inc. is a biotechnology company focused on the development of first in class inhibitors of infectious disease and cancer. Arisyn possesses a portfolio of small molecule compounds that will be developed to treat Human Immunodeficiency Virus-Type 1 (HIV-1), Human Immunodeficiency Virus-Type 2 (HIV-2), Human T-Lymphotropic Virus-Type 1 (HTLV-1), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Herpes Simplex Virus-Type 2 (HSV-2). Arisyn will perform all necessary studies required to develop these therapeutic agents through Phase 1 and Phase 2 human clinical trials.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.